The average one-year price target for Werewolf Therapeutics (NasdaqGS:HOWL) has been revised to $5.30 / share. This is a ...
Werewolf Therapeutics, Inc. (HOWL) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, ...
Director Luke Evnin reported selling shares of Werewolf Therapeutics Inc (NASDAQ:HOWL) between December 2nd and December 4th, 2025. The sales, executed under a prearranged 10b5-1 trading plan, totaled ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback